Analysis of T2 Intensity by Magnetic Resonance Imaging of Deep Gray Matter Nuclei in Multiple Sclerosis Patients: Effect of Immunomodulatory Therapies

Journal of Neuroimaging

Volumn 22, Issue 2, 2012, Pages 137-144

  Pawate, Siddharama ^a   Wang, Lily ^b   Song, Yanna ^b   Sriram, Subramaniam ^a  

^a Multiple Sclerosis Center   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Black T2; Magnetic resonance imaging; T2 hypointensity

Indexed keywords

BETA INTERFERON; GLATIRAMER; IRON; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB;

ADULT; ARTICLE; BRAIN ATROPHY; CEREBELLUM NUCLEUS; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DENTATE NUCLEUS; DISEASE ASSOCIATION; DISEASE DURATION; EXPANDED DISABILITY STATUS SCALE; FEMALE; GLOBUS PALLIDUS; GRAY MATTER; HUMAN; IMAGE ANALYSIS; IMMUNOMODULATION; IMMUNOTHERAPY; IRON STORAGE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHYSICAL DISABILITY; RED NUCLEUS; RETROSPECTIVE STUDY; SUBSTANTIA NIGRA; TREATMENT DURATION; WALKING SPEED;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CEREBELLAR NUCLEI; FEMALE; GLOBUS PALLIDUS; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYCOPHENOLIC ACID; PEPTIDES; RED NUCLEUS; RETROSPECTIVE STUDIES; SUBSTANTIA NIGRA;

EID: 84859723047     PISSN: 10512284     EISSN: 15526569     Source Type: Journal    
DOI: 10.1111/j.1552-6569.2011.00622.x     Document Type: Article

References (38)

1. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008;31:247-269.
2. Rudick RA. Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis. J Neuroimaging 2004;14(3 Suppl):54S-64S.
3. DeLuca GC, Williams K, Evangelou N, et al. The contribution of demyelination to axonal loss in multiple sclerosis. Brain 2006;129(Pt 6):1507-1516.
4. Bitsch A, Schuchardt J, Bunkowski S, et al. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000;123(Pt 6):1174-1183.
5. Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 2003;206(2):165-171.
6. Berg D, Youdim MB. Role of iron in neurodegenerative disorders. Top Magn Reson Imaging 2006;17(1):5-17.
7. Sadrzadeh SM, Saffari Y. Iron and brain disorders. Am J Clin Pathol 2004;121 Suppl:S64-S70.
8. Zecca L, Youdim MB, Riederer P, et al. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 2004;5(11):863-873.
9. Whitnall M, Richardson DR. Iron: a new target for pharmacological intervention in neurodegenerative diseases. Semin Pediatr Neurol 2006;13(3):186-197.
10. Brass SD, Chen NK, Mulkern RV, et al. Magnetic resonance imaging of iron deposition in neurological disorders. Top Magn Reson Imaging 2006;17(1):31-40.
11. Drayer B, Burger P, Hurwitz B, et al. Reduced signal intensity on MR images of thalamus and putamen in multiple sclerosis: increased iron content? AJR Am J Roentgenol 1987;149(2):357-363.
12. Grimaud J, Millar J, Thorpe JW, et al. Signal intensity on MRI of basal ganglia in multiple sclerosis. J Neurol Neurosurg Psychiatry 1995;59(3):306-308.
13. Russo C, Smoker WR, Kubal W. Cortical and subcortical T2 shortening in multiple sclerosis. AJNR Am J Neuroradiol 1997;18(1):124-126.
14. Bakshi R, Shaikh ZA, Janardhan V. MRI T2 shortening ('black T2') in multiple sclerosis: frequency, location, and clinical correlation. Neuroreport 2000;11(1):15-21.
15. Bakshi R, Dmochowski J, Shaikh ZA, et al. Gray matter T2 hypointensity is related to plaques and atrophy in the brains of multiple sclerosis patients. J Neurol Sci 2001;185(1):19-26.
16. Bermel RA, Puli SR, Rudick RA, et al. Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. Arch Neurol 2005;62(9):1371-1376.
17. Tjoa CW, Benedict RH, Weinstock-Guttman B, et al. MRI T2 hypointensity of the dentate nucleus is related to ambulatory impairment in multiple sclerosis. J Neurol Sci 2005;234(1-2):17-24.
18. Zhang Y, Zabad RK, Wei X, et al. Deep grey matter "black T2" on 3 tesla magnetic resonance imaging correlates with disability in multiple sclerosis. Mult Scler 2007;13(7):880-883.
19. Neema M, Arora A, Healy BC, et al. Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging 2009;19(1):3-8.
20. Ceccarelli A, Rocca MA, Neema M, et al. Deep gray matter T2 hypointensity is present in patients with clinically isolated syndromes suggestive of multiple sclerosis. Mult Scler 2010;16(1):39-44.
21. Lynch SG, Fonseca T, Levine SM. A multiple course trial of desferrioxamine in chronic progressive multiple sclerosis. Cell Mol Biol (Noisy-le-grand) 2000;46(4):865-869.
22. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50(1):121-127.
23. Shmueli K, de Zwart JA, van Gelderen P, et al. Magnetic susceptibility mapping of brain tissue in vivo using MRI phase data. Magn Reson Med 2009;62(6):1510-1522.
24. Hammond KE, Metcalf M, Carvajal L, et al. Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron. Ann Neurol 2008;64(6):707-713.
25. Baker DE. Natalizumab: overview of its pharmacology and safety. Rev Gastroenterol Disord 2007;7(1):38-46.
26. Kraus J, Oschmann P. The impact of interferon-beta treatment on the blood-brain barrier. Drug Discov Today 2006;11(15-16):755-762.
27. Bergamini CM, Gambetti S, Dondi A, et al. Oxygen, reactive oxygen species and tissue damage. Curr Pharm Des 2004;10(14):1611-1626.
28. Gaeta A, Hider RC. The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br J Pharmacol 2005;146(8):1041-1059.
29. Gregory A, Hayflick SJ. Neurodegeneration with brain iron accumulation. Folia Neuropathol 2005;43(4):286-296.
30. Boddaert N, Le Quan Sang KH, et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 2007;110(1):401-408.
31. Forni GL, Balocco M, Cremonesi L, et al. Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation. Mov Disord 2008;23(6):904-907.
32. Burgetova A, Seidl Z, Krasensky J, et al. Multiple sclerosis and the accumulation of iron in the Basal Ganglia: quantitative assessment of brain iron using MRI t(2) relaxometry. Eur Neurol 2010;63(3):136-143.
33. Khalil M, Enzinger C, Langkammer C, et al. Quantitative assessment of brain iron by R(2)* relaxometry in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis. Mult Scler 2009;15(9):1048-1054.
34. Bartzokis G, Tishler TA, Shin IS, et al. Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases. Ann N Y Acad Sci 2004;1012:224-236.
35. Ge Y, Jensen JH, Lu H, et al. Quantitative assessment of iron accumulation in the deep gray matter of multiple sclerosis by magnetic field correlation imaging. AJNR Am J Neuroradiol 2007;28:1639-1644.
36. Haacke EM, Makki M, Ge Y, et al. Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging. J Magn Reson Imaging 2009;29(3):537-544.
37. Ceccarelli A, Filippi M, Neema M, et al. T2 hypointensity in the deep gray matter of patients with benign multiple sclerosis. Mult Scler 2009;15(6):678-686.
38. Zamboni P, Galeotti R, Menegatti E, et al. Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2009;80(4):392-399.